RecruitingPhase 2Phase 3NCT07365319

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

Sponsor

Eikon Therapeutics

Enrollment

750 participants

Start Date

Jun 15, 2026

Study Type

INTERVENTIONAL

Conditions

Stage 4 NSCLC Non Small Cell Lung Cancer (Squamous or Non Squamous)

Summary

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called EIK1001, a drug called Nab-paclitaxel + Carboplatin, and others for people with non small cell lung cancer (squamous or non squamous) and stage 4 nsclc. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEIK1001

EIK1001 is a Toll like receptor 7/8 (TLR 7/8) dual agonist

DRUGPembrolizumab (KEYTRUDA®)

PD-1 inhibitor

DRUGPlacebo

Placebo control

DRUGPaclitaxel + Carboplatin

SOC Chemotherapy for squamous NSCLC

DRUGNab-paclitaxel + Carboplatin

SOC Chemotherapy for squamous NSCLC

DRUGPemetrexed + Cisplatin /Carboplatin

SOC Chemotherapy for non-squamous NSCLC

Locations(10)

Southern Cancer Center, P.C.

Daphne, Alabama, United States

Los Angeles Cancer Network

Glendale, California, United States

Rocky Mountain Cancer Centers, LLP

Pueblo, Colorado, United States

NYU Langone Hospital Long Island

Mineola, New York, United States

NYU Langone Hospital Manhattan

New York, New York, United States

White Plains Hospital

White Plains, New York, United States

Blue Ridge Cancer Center

Blacksburg, Virginia, United States

Virginia Cancer Specialists, PC

Fairfax, Virginia, United States

Shenandoah Oncology P.C.

Winchester, Virginia, United States

Institut Catala D'Oncologia de Girona

Girona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07365319

Related Trials

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

NCT062623211 location